Medulloblastoma (Pediatric Brain Tumor)
Medulloblastoma is the most common malignant brain tumor in children, now classified into four molecular subgroups โ WNT, SHH, Group 3, and Group 4 โ with profoundly different outcomes and treatment intensities. SHH-activated tumors may respond to vismodegib, while Group 3 high-risk disease requires aggressive craniospinal radiation and chemotherapy. CancerFax helps families access molecular subgrouping, specialist pediatric neuro-oncology programs, and novel trials.
- WNT/SHH/Group 3/4 molecular subgrouping
- Craniospinal radiation, chemo & hedgehog inhibitor access
- Pediatric neuro-oncology specialist & trial coordination
- Most Common Pediatric Brain Tumor
- ~500 cases/year US
- Median Age at Diagnosis
- 5-8 years
- 5-Year Overall Survival
- ~70-75%
- Four Molecular Subgroups
- WNT, SHH, G3, G4
- WNT Subgroup Survival
- >90%
What is Medulloblastoma
Types and Subtypes
Medulloblastoma is classified into four molecular subgroups based on the WHO 2021 classification. This molecular classification is critical for prognostic assessment and treatment planning. Each subgroup has distinct clinical characteristics, molecular features, and prognosis.
Symptoms and Signs
Medulloblastoma typically presents with progressive neurologic symptoms that develop over weeks to months. Symptoms result from the tumor mass itself and increased intracranial pressure from cerebrospinal fluid obstruction. Early recognition of symptoms is important for timely diagnosis and treatment initiation.
Causes and Risk Factors
Medulloblastoma arises from malignant transformation of cerebellar progenitor cells. The exact etiology is unknown, but specific genetic alterations characterize each molecular subgroup. Most medulloblastomas are sporadic; however, some are associated with inherited cancer syndromes.
Diagnosis and Investigations
Diagnosis of medulloblastoma requires imaging confirmation combined with tissue diagnosis and molecular classification. Accurate diagnosis and molecular subgrouping are essential for prognostic assessment and treatment planning. Metastatic workup is critical for staging and risk stratification.
Disease Staging and Risk Stratification
Medulloblastoma staging uses the Chang staging system based on metastatic status. Risk stratification combines clinical factors (age, metastatic status, residual tumor) with molecular features (subgroup, TP53 status, MYCN amplification). Molecular subgroup is the most important prognostic factor.
Standard Treatment Options
Standard treatment for medulloblastoma consists of three components: maximal surgical resection, craniospinal irradiation, and multi-agent chemotherapy. Treatment is risk-adapted based on molecular subgroup, age, metastatic status, and residual tumor. This multimodal approach has significantly improved outcomes, with 5-year survival rates of 70-75% overall.
Advanced & Emerging Therapies
Advances in medulloblastoma treatment include improved surgical techniques, refined radiation approaches, and emerging targeted therapies. Hedgehog pathway inhibitors for SHH subgroup, immunotherapy approaches, and reduced-dose radiation strategies are expanding treatment options and potentially reducing long-term toxicity.
Targeted Therapy
Hedgehog Pathway Inhibitors
Vismodegib and sonidegib inhibit Sonic Hedgehog signaling. Used for SHH-activated medulloblastoma, particularly TP53-mutant SHH. May allow reduced-intensity chemotherapy and radiation in some cases. Emerging therapy with promising results.
Chemotherapy
High-Dose Chemotherapy with Stem Cell Rescue
Intensive chemotherapy followed by autologous stem cell transplantation. Used for high-risk medulloblastoma (metastatic, high-risk molecular features, residual tumor). Improves progression-free survival in high-risk patients. Associated with significant toxicity.
Radiation Therapy
Proton Therapy
Advanced radiation technique that may reduce radiation dose to normal tissues compared to photon radiation. Potentially reduces long-term toxicity including cognitive impairment and secondary malignancies. Available at select centers.
Radiation Therapy
Reduced-Dose Craniospinal Irradiation
Reduced-dose CSI (18 Gy instead of 23.4 Gy) in selected low-risk cases (WNT subgroup, some SHH cases). Maintains efficacy while reducing long-term toxicity. Particularly important for young children.
Immunotherapy
Checkpoint Inhibitors
Investigational immunotherapy approaches including checkpoint inhibitors. Under investigation for medulloblastoma treatment. May enhance immune response to tumor.
Emerging Therapies
Molecular-Targeted Approaches
Emerging therapies targeting specific molecular alterations in each subgroup. Investigational agents targeting MYC pathway in Group 3, chromosome 11 alterations in Group 4. Clinical trials evaluating novel combinations.
Biomarkers & Molecular Features
Molecular and clinical biomarkers in medulloblastoma provide critical prognostic information and guide treatment decisions. Molecular subgroup is the most important prognostic factor, followed by TP53 mutation status, MYCN amplification, and clinical factors.
When to Seek a Second Opinion
Expert review is valuable in medulloblastoma given the complexity of diagnosis, molecular subgrouping, risk stratification, and multimodal treatment. Second opinion is recommended at multiple points in the treatment course.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis for medulloblastoma varies dramatically by molecular subgroup and clinical risk factors. Overall 5-year survival is 70-75%, but ranges from >90% for WNT subgroup to 40-50% for Group 3. Modern multimodal therapy has significantly improved outcomes compared to historical data.
Supportive Care & Living With Medulloblastoma
Supportive care is an essential component of medulloblastoma treatment and long-term follow-up, addressing both the acute effects of treatment and long-term complications. Families need comprehensive support throughout the treatment course and beyond.
How CancerFax Helps You Explore Treatment Options
CancerFax assists families with medulloblastoma by coordinating expert review of diagnostic brain MRI, tissue biopsy pathology, molecular subgrouping (WNT, SHH, Group 3, Group 4), TP53 and MYCN status, CSF cytology, spinal imaging, and clinical presentation to confirm accurate diagnosis and disease extent. We connect families with pediatric neurosurgeons, pediatric neuro-oncologists, and radiation oncologists experienced in medulloblastoma management. We facilitate access to maximal surgical resection, craniospinal irradiation, multi-agent chemotherapy, targeted therapy (hedgehog inhibitors for SHH), high-dose chemotherapy with stem cell rescue, proton therapy, and clinical trial opportunities at major pediatric cancer centers globally, including specialized institutions in China.
Get a free case reviewFrequently Asked Questions
Medulloblastoma is the most common malignant brain tumor in children, accounting for approximately 20% of all childhood brain tumors. It is a fast-growing embryonal tumor that arises from progenitor cells in the cerebellum, the part of the brain that controls movement, balance, and posture. Approximately 500 new cases are diagnosed annually in the United States, with a median age at diagnosis of 5-8 years.
Medulloblastoma is classified into four molecular subgroups: (1) WNT (10% of cases) with excellent prognosis (>90% 5-year survival); (2) SHH (28% of cases) with variable prognosis depending on TP53 status; (3) Group 3 (27% of cases) with poor prognosis (40-50% 5-year survival); (4) Group 4 (34% of cases) with intermediate prognosis (50-70% 5-year survival). Molecular subgroup is the most important prognostic factor and guides treatment approach.
Symptoms typically develop over weeks to months and include headache (often worse in morning), nausea and vomiting (often worse in morning), balance problems and coordination difficulties, vision problems, hearing loss, facial weakness, and behavioral changes. Symptoms result from the tumor mass and increased intracranial pressure from cerebrospinal fluid obstruction.
Diagnosis requires brain MRI showing a tumor in the cerebellum. Tissue diagnosis is obtained through surgical resection or biopsy. Molecular testing determines the subgroup (WNT, SHH, Group 3, Group 4). Spinal MRI and CSF cytology assess metastatic disease. TP53 and MYCN status are determined for prognostic assessment.
Standard treatment consists of three components: (1) maximal surgical resection of the tumor; (2) craniospinal irradiation (radiation to brain and spinal cord); (3) multi-agent chemotherapy. Treatment is risk-adapted based on molecular subgroup, age, metastatic status, and residual tumor. WNT subgroup may benefit from reduced-intensity therapy. Group 3 and high-risk Group 4 require intensive therapy.
Craniospinal irradiation (CSI) is radiation therapy delivered to the entire brain and spinal cord to treat microscopic metastatic disease. Standard dose is 23.4 Gy to the brain and spinal cord, with additional boost (32 Gy total) to the tumor bed. Reduced-dose CSI (18 Gy) may be used in selected low-risk cases. CSI is typically started 3-4 weeks after surgery.
Long-term effects include cognitive impairment (most significant), growth hormone deficiency, hearing loss (from cisplatin), thyroid dysfunction, cardiac effects (from doxorubicin), infertility (from high-dose chemotherapy), and increased risk of secondary malignancies. Long-term follow-up and management of late effects are important parts of survivorship care.
Overall 5-year survival is 70-75%. WNT subgroup has excellent prognosis (>90% 5-year survival). SHH non-TP53 mutant has good prognosis (70-80%). Group 3 has worst prognosis (40-50%). Group 4 has intermediate prognosis (50-70%). Standard-risk patients have ~80-90% 5-year survival; high-risk patients have ~40-60% 5-year survival.
Yes. CancerFax helps families with medulloblastoma by coordinating expert review of diagnostic imaging, tissue biopsy, molecular subgrouping, and clinical presentation. We connect families with pediatric neurosurgeons and neuro-oncologists experienced in medulloblastoma management. We facilitate access to multimodal treatment including surgery, radiation, chemotherapy, targeted therapy, and clinical trial opportunities at major pediatric cancer centers.